Interfering with S100B–effector protein interactions for cancer therapy

Ke Jia Wu, Wanhe Wang, Hui Min David Wang, Chung Hang Leung*, Edmond Dik Lung MA

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

1 Citation (Scopus)

Abstract

S100 calcium-binding protein B (S100B) is overexpressed in various malignant tumors, where it regulates cancer cell proliferation and metabolism by physical interactions with other molecules. Interfering with S100B–effector protein interactions is a potential strategy to treat malignant tumors. Although some S100B inhibitors have been discovered by virtual screening (VS), most target the S100B–p53 interaction. Hence, there is scope for the discovery of other S100B–effector protein interaction modulators for malignant tumors. In this review, we provide an overview of S100B–effector protein interaction inhibitor discovery using VS and discuss promising S100B–effector protein interaction targets that permit in silico analysis for drug discovery.

Original languageEnglish
Pages (from-to)1754-1761
Number of pages8
JournalDrug Discovery Today
Volume25
Issue number9
DOIs
Publication statusPublished - Sep 2020

Scopus Subject Areas

  • Pharmacology
  • Drug Discovery

Fingerprint

Dive into the research topics of 'Interfering with S100B–effector protein interactions for cancer therapy'. Together they form a unique fingerprint.

Cite this